AMAG Pharmaceuticals, Inc. AMAG Cash Flow

Amag pharmaceuticals, inc. (AMAG)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	2,978	26,195	-	26,302	31,989	27	-	-	-	8,880	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from operating activities:
Net loss
-24,491	-199,928	-23,617	-120,827	-122,084	-22,277	30,840	-20,082	-54,242	3,460	-152,062	-14,066	-36,560	-10,557	16,197	-596	-7,527	7,201	-20,584	33,258	12,904	143,008	1,458	-1,547	-7,102	-3,654	-145	-1,908	-3,895	-3,686	-3,967	3,319	-12,416	-18,581	-16,631	-19,562	-22,295	-19,780	-16,996	-21,324	-23,053
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
10,318	13,453	4,782	4,714	4,375	14,221	31,819	66,698	59,485	66,597	29,378	31,569	27,994	30,926	27,729	21,587	19,644	17,757	16,971	19,856	14,519	6,329	275	218	162	150	1,596	689	650	342	1,320	871	551	570	649	675	642	624	607	604	570
Provision for bad debt expense
223	12	0	4	-16	-76	-102	393	463	349	822	2,091	590	1,000	2,209	-2,209	2,209	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premium/discount on purchased securities
-4	31	13	24	27	9	-3	-26	-67	-84	-50	-55	-113	-106	-167	-174	-177	-647	-847	-602	-56	-257	-567	-592	-664	-682	-707	-688	-681	-627	-718	-697	-766	-861	-937	-973	-868	-775	-646	-225	-33
Write-down of inventory
616	14,928	36	4,836	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	190	251	-569	1,437	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash equity-based compensation expense
3,868	4,817	4,974	4,534	4,873	5,317	3,477	5,589	5,533	5,606	6,389	5,891	5,778	5,734	5,467	5,182	6,160	5,665	4,888	4,016	2,668	2,472	1,946	2,277	1,930	2,118	1,665	1,938	2,283	1,712	2,050	1,577	1,685	1,240	1,702	2,621	4,475	3,787	1,500	4,935	4,301
Non-cash IPR&D expense
0	0	0	0	18,029	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount and debt issuance costs
4,004	3,910	3,819	3,730	3,783	3,834	3,973	3,971	3,880	3,795	3,921	3,470	3,209	3,090	3,075	3,003	2,937	2,916	2,962	3,100	2,401	2,339	1,879	1,801	851	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gains on marketable securities, net
9	2	-7	270	0	-	-	-	-	-325	6	106	143	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Gains) on sale of assets held for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	299	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on sale of investments, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-24	0	0	-	-	-	-	-	-	-	-	4	4	26	6	-	-	-	-	1	14	-209	1	6	-396	794	4
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent consideration
0	-254	5	-15	-6	-432	9	-49,810	626	-544	-49,928	1,743	1,043	20,577	3,707	-3,657	5,056	-254	2,886	-960	2,599	1,854	-3,713	389	789	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash lease expense
451	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income taxes
630	-	-222	172	458	-	1,375	49,015	-6,643	-	-117,005	-8,485	-21,192	-	3,944	98	-1,469	-12,550	-6,086	18,035	5,608	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash lease expense
451	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of assets
1,409	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
12,547	16,587	-5,596	-146	7,971	-9,820	-18,440	14,358	-3,093	6,089	9,122	6,320	-6,553	23,296	6,202	-18,877	-715	12,838	6,226	-155	18,004	-7,619	292	466	3,273	-1,936	288	-29	2,109	-953	1,585	-500	346	-1,137	2,256	-1,696	724	-1,863	-6,582	-774	-12,346
Inventories
2,770	12,429	3,501	350	2,973	4,041	-2,364	2,311	-3,534	1,731	-545	742	403	986	1,650	-2,438	2,157	4,224	-14	4,353	-3,326	-1,136	-71	46	2,521	1,680	55	1,139	-1,834	-807	-1,584	453	-2,131	1,273	-1,066	-715	-313	-482	1,370	3,287	2,500
Receivable from collaboration
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-182	-246	428	-5,615	5,615	-4,518	3,585	702	28	-76	28	-118	260	-155	-514	-14,356	14,763	-58	236	-679	20	410	-	-	-	-
Prepaid and other current assets
6,490	-23,962	18,513	-16,018	21,580	7,198	-1,857	-2,964	3,720	813	231	2,701	-1,523	-5,388	1,020	-2,805	3,078	-4,123	3,420	-255	-3,076	-4,542	786	411	1,014	-2,504	242	-561	6	-1,414	3,425	-1,538	-548	502	219	-1,174	-1,208	256	2,763	30	-572
Other long-term assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136	-252	-885	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-19,671	-345	17,613	4,047	31,432	-28,288	-31,755	-2,899	30,374	-13,143	-10,739	45,338	-4,622	29,097	15,240	11,347	-6,647	11,889	-14,244	5,379	4,852	10,607	602	586	-1,101	1,303	-944	985	-7,074	1,191	-6,840	-4,083	-2,463	-3,385	3,670	4,921	-3,508	2,365	-3,549	6,631	-2,702
Deferred revenues
-	-	-	-	-	0	1,329	4,302	3,027	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues
-	-	-	-	-	-	-	-	-	-	-	-	2,067	-	4,684	7,487	9,717	13,378	8,801	-33,563	-10,813	-1,725	-1,481	-2,103	-3,075	-1,695	-1,216	-1,967	-1,816	11,580	-620	-1,524	-1,524	-1,524	-1,524	-1,595	-1,710	-3,005	-4,967	56,609	-1,940
Other assets and liabilities
-664	2,838	245	516	-1,799	64	-42	98	-215	84	110	543	486	1,497	503	-1,377	-593	-4,263	554	-1,849	-1,686	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-46,609	-19,965	-9,279	-6,544	-89,908	-24,093	-235	39,436	45,692	19,948	28,216	72,968	-14,536	62,520	73,068	84,058	26,576	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43,916	-12,447
Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities
11,255	13,000	38,901	18,475	27,945	25,196	16,108	25,813	18,225	15,431	28,509	122,505	128,512	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
23,345	0	0	0	14,815	25,556	17,674	25,624	21,102	16,355	25,645	-43,992	129,241	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-90	-91	318	59	-78	-116	-111	-103	-103	-102	-97	-89	-88	-89	-83	-75	-74	-75	-70
Total adjustments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,385	-3,972	-	1,538	1,318	-5,818	20,497	7,954	-14,167	1,309	-3,076	4,387	10,884	1,070	6,658	-2,878	65,240	10,606
Net cash provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13,604	42,292	29,396	-	-154	838	-11,074	2,136	1,393	-590	-9,713	16,811	3,987	-10,848	-11,107	-21,657	-12,244	-8,678	-21,225	-	-	-	-
Proceeds from sales or maturities of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	29,233	17,000	25,500	134,945	67,557	5,005	1,459	164,976	9,886	22,000	26,706	21,576	20,687	33,104	30,663	30,521	17,306	47,730	37,504	41,999	28,063	35,706	35,327	49,794	42,810	58,525	8,950
Purchase of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	43,380	35,382	63,413	98,679	34,995	197,190	93,895	0	16,418	22,283	25,046	26,417	18,976	35,747	33,906	44,101	9,127	43,973	52,205	32,878	19,795	24,548	49,364	-	-	-	-
Change in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	0	0	0	-2,883	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from the sale of assets
1,440	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital expenditures
68	446	191	113	1,794	621	360	630	923	2,415	3,901	2,014	658	-	-	-	-	-	-	-	-	-	-	11	124	-	-	-	23	0	0	0	47	92	203	136	76	123	457	426	217
Capital expenditures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	681	819	-237	622	55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-10,718	12,554	-21,290	18,362	11,336	-10,981	517,377	-441	-3,800	-3,339	-10,337	117,983	-1,387	1,098	-14,920	-20,288	-38,594	35,062	-649,367	-192,245	-92,491	-430,628	-6,541	-292	4,519	-5,697	505	-5,845	-2,898	-13,580	8,179	3,757	-14,748	9,029	8,065	11,022	-14,113	21,119	-11,773	-121,820	8,733
Cash flows from financing activities:
Proceeds from sale of assets held for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	368	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	218,613	-286	189,150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	165,559
Long-term debt principal payments
-	-	-	-	-	-	-	-	-	-	0	323,750	4,375	4,375	4,375	4,377	4,375	0	310,823	8,501	8,185	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Convertible Debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	200,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments to settle convertible notes
0	0	0	0	21,417	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of Debt Issuance Costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,049	0	350	6,361	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of contingent consideration
17	22	23	10	17	32	27	16	44	39,628	46	36	83	91,918	63	84	65	134	132	106	84	84	96	59	31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	25,620	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of convertible bond hedges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	39,760	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for repurchases of common stock
0	0	0	0	13,730	0	0	0	0	-	-	-	-	0	0	12,438	7,562	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of common stock options
0	0	0	-3	33	1,246	1,162	1,350	123	671	1,220	978	152	-	-	-	400	-	3,834	4,929	6,719	5,590	888	1,004	1,017	-352	1,250	216	163	-	-	-	-	111	0	0	10	15	238	308	776
Payments of employee tax withholding related to equity-based compensation
1,210	13	69	112	1,636	50	270	14	2,348	108	149	1,117	1,322	0	156	319	1,696	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-1,227	620	-92	726	-36,767	1,164	-502,189	1,320	-2,269	-84,406	-20,084	-183,526	-5,628	-94,592	-3,979	-16,049	-13,298	-11,784	740,617	-3,964	187,600	331,966	792	595	180,485	-399	1,246	392	163	-	-	-	-	325	0	294	10	265	238	950	166,335
Net decrease in cash, cash equivalents, and restricted cash
-58,554	-6,791	-30,661	12,544	-115,339	-33,910	14,953	40,315	39,623	-67,797	-2,205	7,425	-21,551	-30,974	54,169	47,721	-25,316	61,175	77,646	-153,917	124,505	-76,858	-5,903	1,141	173,930	-3,960	3,144	-6,043	-12,448	3,393	12,222	-6,941	-25,855	-12,303	-4,179	2,638	-35,328	8,262	-31,409	-76,954	162,621
Supplemental data for cash flow information:
Cash (refunded) paid for taxes
-256	-	-	-	78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for taxes
-	-	-	-	-	-	860	4,045	136	-	374	2,983	208	698	708	3,900	2	-	-	-	238	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
0	5,200	0	5,200	267	5,211	19,375	5,200	18,971	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Settlement of note receivable in connection with Perosphere acquisition
0	0	0	0	10,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities
0	-	-	-	918	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-